[Discussion] regulatory is doing more work than we give it credit for
regulatory is doing more work than we give it credit for — a position I have arrived at slowly and would like tested.
Regulatory classification differs between jurisdictions and has changed in several of them recently. Any answer to a status question needs a place and a date attached.
Paid for identity confirmation rather than just purity for the first time here. Worth it, and it is not the default on most certificates.
Ask for the theoretical mass alongside the measured one. It is a one-line addition to a certificate and it converts a purity claim into an identity claim.
Screenshot none of this. Read the whole thread, including the parts where I am told I am wrong.
best — the order this archive was captured in
Research-use-only material is not approved for human use. In this board that is not a formality — it is the reason the clinical evidence base is as thin as it is.
Is that a clinical claim or a preclinical one?
What jurisdiction are you asking about? The answer has changed in several.
Which paper is that claim from, and was it in humans?
Not convinced. A high purity figure with no identity confirmation tells you the sample is homogeneous, not that it is what you ordered.
short peptides are cheap, which cuts both ways
Purity by area percent tells you the sample is homogeneous. Mass spectrometry tells you what the homogeneous thing is. For a short peptide, the second question is the one worth paying for.
The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.
Reconstituted or powder, and how long has it been in solution?
It is a fifteen-residue peptide with a published sequence, which makes synthesis straightforward and makes identity verification the meaningful test rather than an optional extra.
Was there identity confirmation, or only a purity figure?
Small fix — fifteen residues, not seventeen. The sequence is public and easy to check.
Went and read the primary rodent papers after arguing about a summary for a week. They are much narrower than the threads suggest.
Short peptides in solution are subject to hydrolysis and, depending on sequence, oxidation. Storage state and time in solution are practical variables that this board almost never discusses.
[deleted]
research-use-only means not approved for human use, and here that covers everything
Bought small, tested identity first, and only then thought about anything else. That order felt right.
ask for the mass spectrum, not just the purity number
identity, quantity, stability — three separate questions
sequence confirmation is the test worth paying for
Agreed. Identity is the question here. A short peptide can be synthesised by almost anyone and the sequence is what you are actually buying.
- 1Short peptides in solution are subject to hydrolysis and, depending on…8 comments in this branch · started by u/baseline_drifter